MTEM

Molecular Templates, Inc.

1.57 USD
+0.16 (+11.35%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Molecular Templates, Inc. stock is up 4.67% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 19 May’s closed higher than April.

About Molecular Templates, Inc.

Molecular Templates, Inc. develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45.